论文部分内容阅读
目的探讨联合高压臭氧自体血回输治疗对干扰素治疗慢性丙型肝炎(CHC)患者临床疗效和不良反应的影响。方法 105例CHC患者被分为对照组(52例,皮下注射干扰素和口服利巴韦林)和治疗组(53例,皮下注射干扰素和口服利巴韦林,联合应用高压臭氧自体血回输疗法,平均10~16次),疗程均为48周,随访24周,观察病毒学应答率和不良反应发生率。结果联合治疗组患者合并血清甘油三酯、高血压和糖尿病的发生率分别为28.3%、28.3%和28.3%,显著高于对照组的5.8%、7.7%和7.7%(P<0.05),但两组患者在性别构成比、平均年龄、肝功能、HCV RNA载量和肝硬化患者比率等方面差异无统计学意义;治疗前后两组肝功能指标变化的差异无统计学意义;治疗组患者发热、流感样症状和血红蛋白减低发生率分别为50.9%、35.8%和34.0%,显著低于对照组的73.1%、59.6%和55.8%(x2=5.5,P<0.01;x2=5.9,P<0.01和x2=5.0,P<0.01);治疗组早期病毒学应答率、治疗结束时应答率和持续应答率分别为83.0%、83.0%和74.4%,与对照组相比无显著统计学差异(分别为88.5%、86.5%和76.3%)。结论尽管合并高代谢综合征,干扰素联合高压臭氧自体血回输治疗CHC患者病毒学应答率与对照组无显著性差异,但显著减少了不良反应发生率。高压臭氧自体血回输治疗可能成为减少干扰素不良反应的辅助疗法。
Objective To investigate the effects of combined hyperbaric ozone autologous blood transfusion on the clinical efficacy and adverse reactions of interferon in patients with chronic hepatitis C (CHC). Methods One hundred and fifty patients with CHC were divided into control group (52 cases, subcutaneous injection of interferon and oral ribavirin) and treatment group (53 cases, subcutaneous injection of interferon and oral ribavirin, combination of high pressure ozone autologous blood back Infusion therapy, an average of 10 to 16 times), the course of treatment were 48 weeks, followed up for 24 weeks to observe the virological response rate and incidence of adverse reactions. Results The incidence of combined triglyceride, hypertension and diabetes was 28.3%, 28.3% and 28.3% in the combined treatment group, significantly higher than those in the control group (5.8%, 7.7% and 7.7%, respectively) There was no significant difference in gender composition ratio, mean age, liver function, HCV RNA load and the proportion of patients with cirrhosis between the two groups. There was no significant difference in the changes of liver function between the two groups before and after treatment. The patients in the treatment group had fever , Flu-like symptoms and the incidence of hemoglobin decrease were 50.9%, 35.8% and 34.0% respectively, which were significantly lower than 73.1%, 59.6% and 55.8% in the control group (x2 = 5.5, P <0.01; And x2 = 5.0, P <0.01). The early virological response rate in the treatment group was 83.0%, 83.0% and 74.4% at the end of treatment, respectively, with no significant difference compared with the control group 88.5%, 86.5% and 76.3%). Conclusions Despite the high metabolic syndrome, interferon combined with autologous hypervascular ozone autotransfusion treatment of CHC patients virological response rate was no significant difference with the control group, but significantly reduced the incidence of adverse reactions. High-pressure ozone autologous blood transfusion may be an adjunct therapy to reduce the adverse reactions of interferon.